izpis_h1_title_alt

Synthesis, molecular modelling and biological evaluation of novel heterodimeric, multiple ligands targeting cholinesterases and amyloid beta
ID Hebda, Michalina (Author), ID Bajda, Marek (Author), ID Więckowska, Anna (Author), ID Szałaj, Natalia (Author), ID Pasieka, Anna (Author), ID Panek, Dawid (Author), ID Godyń, Justyna (Author), ID Wichur, Tomasz (Author), ID Knez, Damijan (Author), ID Gobec, Stanislav (Author), ID Malawska, Barbara (Author)

.pdfPDF - Presentation file, Download (3,87 MB)
MD5: 2B82C8E2840666F94BA09522EC4B788F
URLURL - Source URL, Visit http://www.mdpi.com/1420-3049/21/4/410 This link opens in a new window

Abstract
Cholinesterases and amyloid beta are one of the major biological targets in the search for a new and efficacious treatment of Alzheimer's disease. The study describes synthesis and pharmacological evaluation of new compounds designed as dual binding site acetylcholinesterase inhibitors. Among the synthesized compounds, two deserve special attention-compounds 42 and 13. The former is a saccharin derivative and the most potent and selective acetylcholinesterase inhibitor (EeAChE IC$_5$$_0$ = 70 nM). Isoindoline-1,3-dione derivative 13 displays balanced inhibitory potency against acetyl- and butyrylcholinesterase (BuChE) (EeAChE IC$_5$$_0$ = 0.76 µM, EqBuChE IC$_5$$_0$ = 0.618 µM), and it inhibits amyloid beta aggregation (35.8% at 10 µM). Kinetic studies show that the developed compounds act as mixed or non-competitive acetylcholinesterase inhibitors. According to molecular modelling studies, they are able to interact with both catalytic and peripheral active sites of the acetylcholinesterase. Their ability to cross the blood-brain barrier (BBB) was confirmed in vitro in the parallel artificial membrane permeability BBB assay. These compounds can be used as a solid starting point for further development of novel multifunctional ligands as potential anti-Alzheimer's agents.

Language:English
Keywords:cholinesterase inhibitors, molecular modelling, β-amyloid aggregation inhibitors, Alzheimer’s disease, multi-target-directed ligands (MTDL), PAMPA-BBB assay
Work type:Article (dk_c)
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Year:2016
Publication status in journal:Published
Article version:Publisher's version of article
Number of pages:24 str.
Numbering:Vol. 21, iss. 4, art. 410
PID:20.500.12556/RUL-130296 This link opens in a new window
UDC:615.2:616.894
ISSN on article:1420-3049
DOI:10.3390/molecules21040410 This link opens in a new window
COBISS.SI-ID:4051313 This link opens in a new window
Publication date in RUL:13.09.2021
Views:201
Downloads:67
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Share:AddThis
AddThis uses cookies that require your consent. Edit consent...

Record is a part of a journal

Title:Molecules
Shortened title:Molecules
Publisher:MDPI
ISSN:1420-3049
COBISS.SI-ID:18462981 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.04.2016

Secondary language

Language:Slovenian
Keywords:tarčna zdravila, razvoj zdravil, zaviralci acetilholinesteraze, molekularno modeliranje, Alzheimerjeva bolezen

Projects

Funder:Drugi - Drug financer ali več financerjev
Funding programme:Polish Ministry for Science and High Education
Project number:N N405 163339

Funder:Drugi - Drug financer ali več financerjev
Funding programme:National Science Center of Poland
Project number:2012/07/B/NZ7/04253

Funder:Drugi - Drug financer ali več financerjev
Funding programme:Jagiellonian University Collegium Medicum
Project number:K/Z S/004657

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back